Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Prostatic Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Rituximab 2Sodium Chloride 1Pentostatin 1Monatide (IMS 3015) 1Magnetic Resonance Imaging 1Histamine Antagonists 1Exercise Test 1Epinephrine 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Cyclophosphamide 1Cladribine 1Celecoxib 1Caves 1Bronchodilator Agents 1Biological Assay 1Bendamustine Hydrochloride 1Adrenal Cortex Hormones 1Acetaminophen 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasm, Residual × ALT-803 × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡